Paper37573009
Consideration of vendor-related differences in hepatic metabolic stability data to optimize early ADME screening in drug discovery.
Shah P and 5 others. SLAS Discov, 2024. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Consideration of vendor-related differences in hepatic metabolic stability data to optimize early ADME screening in drug discovery. Papers, record 37573009. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37573009
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Consideration of vendor-related differences in hepatic metabolic stability data to optimize early ADME screening in drug discovery.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Liver | Major topic |
| Drug Discovery | Major topic |
| Rats | |
| Animals | |
| Microsomes, Liver | |
| Biological Availability | |
| Drug Evaluation, Preclinical |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Z99 TR999999 | Intramural NIH HHS | United States | Z99TR999999 | PubMed | NIH RePORTER |
| ZIATR000369 | NIH | NIH RePORTER |
References19
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 14567798 | Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates. | J Biomol Screen | 2003 | https://conductscience.org/library/papers/14567798 | PubMed |
| 2 | 15230342 | Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data? | Eur J Drug Metab Pharmacokinet | 2004 | https://conductscience.org/library/papers/15230342 | PubMed |
| 3 | 34176369 | Validating ADME QSAR Models Using Marketed Drugs. | SLAS Discov | 2021 | https://conductscience.org/library/papers/34176369 | PubMed |
| 4 | 23333322 | Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. | Pharmacol Ther | 2013 | https://conductscience.org/library/papers/23333322 | PubMed |
| 5 | 33992989 | NOX2 inhibitor GSK2795039 metabolite identification towards drug optimization. | J Pharm Biomed Anal | 2021 | https://conductscience.org/library/papers/33992989 | PubMed |
| 6 | 16790553 | Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. | Drug Metab Dispos | 2006 | https://conductscience.org/library/papers/16790553 | PubMed |
| 7 | 10836130 | High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. | Annu Rev Pharmacol Toxicol | 2000 | https://conductscience.org/library/papers/10836130 | PubMed |
| 8 | 18220563 | The conduct of drug metabolism studies considered good practice (II): in vitro experiments. | Curr Drug Metab | 2007 | https://conductscience.org/library/papers/18220563 | PubMed |
| 9 | 34183376 | Development of Robust Quantitative Structure-Activity Relationship Models for CYP2C9, CYP2D6, and CYP3A4 Catalysis and Inhibition. | Drug Metab Dispos | 2021 | https://conductscience.org/library/papers/34183376 | PubMed |
| 10 | 33431020 | Predicting liver cytosol stability of small molecules. | J Cheminform | 2020 | https://conductscience.org/library/papers/33431020 | PubMed |
| 11 | 32125203 | In vitro-in vivo extrapolation of metabolic clearance using human liver microsomes: factors showing variability and their normalization. | Xenobiotica | 2020 | https://conductscience.org/library/papers/32125203 | PubMed |
| 12 | 31898492 | An in vitro toolbox to accelerate anti-malarial drug discovery and development. | Malar J | 2020 | https://conductscience.org/library/papers/31898492 | PubMed |
| 13 | 12612645 | ADMET in silico modelling: towards prediction paradise? | Nat Rev Drug Discov | 2003 | https://conductscience.org/library/papers/12612645 | PubMed |
| 14 | 33244000 | Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models. | Sci Rep | 2020 | https://conductscience.org/library/papers/33244000 | PubMed |
| 15 | 27417180 | An Automated High-Throughput Metabolic Stability Assay Using an Integrated High-Resolution Accurate Mass Method and Automated Data Analysis Software. | Drug Metab Dispos | 2016 | https://conductscience.org/library/papers/27417180 | PubMed |
| 16 | 35350742 | Physiologically based pharmacokinetic (PBPK) modeling and simulation in drug discovery and development. | ADMET DMPK | 2019 | https://conductscience.org/library/papers/35350742 | PubMed |
| 17 | 35435491 | Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. | Arch Toxicol | 2022 | https://conductscience.org/library/papers/35435491 | PubMed |
| 18 | 27636111 | In Vitro Drug Metabolism Using Liver Microsomes. | Curr Protoc Pharmacol | 2016 | https://conductscience.org/library/papers/27636111 | PubMed |
| 19 | 11727321 | The prediction of human clearance from hepatic microsomal metabolism data. | Curr Opin Drug Discov Devel | 2001 | https://conductscience.org/library/papers/11727321 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42562981 | The Enzyme-Bag Platform for Cytochrome P450 Biotransformation and High-Throughput Drug Metabolism Screening. | Methods Mol Biol | 2026 | https://conductscience.org/library/papers/42562981 | PubMed |
| 42137024 | Assessing the impact of data harmonization on human liver microsomal stability prediction model performance. | Results Chem | 2026 | https://conductscience.org/library/papers/42137024 | PubMed |
| 41530259 | Comparative analysis of sex-based, vendor-based, and species differences in cytochrome P450 metabolism. | Sci Rep | 2026 | https://conductscience.org/library/papers/41530259 | PubMed |
| 41503944 | In Vitro Pharmacokinetic Profiling of Thiourea Derivatives of Naproxen With Anti-Inflammatory and Anticancer Activity. | Chem Biodivers | 2026 | https://conductscience.org/library/papers/41503944 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CYP2C9 | 1559 | PubTator's text mining | https://conductscience.org/library/genes/1559 | NCBI Gene |
| CYP2D6 | 1565 | PubTator's text mining | https://conductscience.org/library/genes/1565 | NCBI Gene |
| CYP3A4 | 1576 | PubTator's text mining | https://conductscience.org/library/genes/1576 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37573009
GET https://conductscience.org/api/papers/v1/37573009/authors